The Metabolic Remodelling in Lung Cancer and Its Putative Consequence in Therapy Response
- PMID: 32130706
- DOI: 10.1007/978-3-030-34025-4_16
The Metabolic Remodelling in Lung Cancer and Its Putative Consequence in Therapy Response
Abstract
Lung cancer is the leading cause of cancer-related deaths worldwide in both men and women. Conventional chemotherapy has failed to provide long-term benefits for many patients and in the past decade, important advances were made to understand the underlying molecular/genetic mechanisms of lung cancer, allowing the unfolding of several other pathological entities. Considering these molecular subtypes, and the appearance of promising targeted therapies, an effective personalized control of the disease has emerged, nonetheless benefiting a small proportion of patients. Although immunotherapy has also appeared as a new hope, it is still not accessible to the majority of patients with lung cancer.The metabolism of energy and biomass is the basis of cellular survival. This is true for normal cells under physiological conditions and it is also true for pathophysiologically altered cells, such as cancer cells. Thus, knowledge of the metabolic remodelling that occurs in cancer cells in the sense of, on one hand, surviving in the microenvironment of the organ in which the tumour develops and, on the other hand, escaping from drugs conditioned microenvironment, is essential to understand the disease and to develop new therapeutic approaches.
Keywords: Lung cancer; Metabolic remodelling; New therapeutic approaches; Targeted therapy; Tumor microenvironment.
Similar articles
-
Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer.Curr Cancer Drug Targets. 2019;19(8):595-630. doi: 10.2174/1568009619666181210114559. Curr Cancer Drug Targets. 2019. PMID: 30526458 Review.
-
Lung cancer stem cells: origin, features, maintenance mechanisms and therapeutic targeting.Biochem Pharmacol. 2019 Feb;160:121-133. doi: 10.1016/j.bcp.2018.12.010. Epub 2018 Dec 14. Biochem Pharmacol. 2019. PMID: 30557553 Review.
-
The biology and management of non-small cell lung cancer.Nature. 2018 Jan 24;553(7689):446-454. doi: 10.1038/nature25183. Nature. 2018. PMID: 29364287 Review.
-
Immunotherapy in NSCLC: A Promising and Revolutionary Weapon.Adv Exp Med Biol. 2017;995:97-125. doi: 10.1007/978-3-319-53156-4_5. Adv Exp Med Biol. 2017. PMID: 28321814 Review.
-
Mechanisms of resistance to chemotherapy in non-small cell lung cancer.Arch Pharm Res. 2021 Feb;44(2):146-164. doi: 10.1007/s12272-021-01312-y. Epub 2021 Feb 19. Arch Pharm Res. 2021. PMID: 33608812 Review.
Cited by
-
H2S-Synthesizing Enzymes Are Putative Determinants in Lung Cancer Management toward Personalized Medicine.Antioxidants (Basel). 2023 Dec 28;13(1):51. doi: 10.3390/antiox13010051. Antioxidants (Basel). 2023. PMID: 38247476 Free PMC article.
-
A metabolomics study on carcinogenesis of ground-glass nodules.Cytojournal. 2024 Mar 18;21:12. doi: 10.25259/Cytojournal_68_2023. eCollection 2024. Cytojournal. 2024. PMID: 38628288 Free PMC article.
-
Metabolic profiling and combined therapeutic strategies unveil the cytotoxic potential of selenium-chrysin (SeChry) in NSCLC cells.Biosci Rep. 2024 Jul 31;44(7):BSR20240752. doi: 10.1042/BSR20240752. Biosci Rep. 2024. PMID: 38990147 Free PMC article.
References
-
- Abrams JA, Lee PC, Port JL et al (2008) Cigarette smoking and risk of lung metastasis from esophageal cancer. Cancer Epidemiol Biomark Prev 17:2707–2713. https://doi.org/10.1158/1055-9965.EPI-08-0232 - DOI
-
- Achek A, Kwon H, Lee B, Yoo TH (2017) TLR4/MD2 specific peptides stalled in vivo LPS-induced immune exacerbation. Biomaterials 126:49–60. https://doi.org/10.1016/j.biomaterials.2017.02.023 - DOI - PubMed
-
- Adekola K, Rosen ST, Shanmugam M (2012) Glucose transporters in cancer metabolism. Curr Opin Oncol 24:650–654. https://doi.org/10.1097/CCO.0b013e328356da72 - DOI - PubMed - PMC
-
- Agrawal NR, Bukowski RM, Rybicki LA et al (2003) A phase I-II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myeloma. Cancer 98:94–99. https://doi.org/10.1002/cncr.11480 - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous